8-K: Delcath Systems Boosts 2026 Revenue Outlook

Delcath Systems reported Q2 2026 results, showing revenue growth and raising full-year revenue guidance, though adjusted EBITDA and operating cash flow saw a year-over-year decrease.

Summary

• Delcath Systems announced its second quarter 2026 financial results, reporting total revenue of $29.1 million, an increase from $24.2 million in Q2 2025.
• HEPZATO KIT revenue reached $27.1 million, up from $22.5 million in the prior year's quarter, while CHEMOSAT revenue was $2.0 million, up from $1.7 million.
• Gross margins improved to 90% from 86% in Q2 2025.
• Net income remained stable at $2.7 million for both Q2 2026 and Q2 2025.
• Non-GAAP adjusted EBITDA decreased to $7.6 million from $9.8 million in Q2 2025.
• Cash provided by operations was $5.7 million, down from $7.3 million in Q2 2025.
• The company raised its 2026 full-year revenue guidance to a range of $104 million to $108 million, expecting at least 28% growth in HEPZATO KIT volume over 2025.
• As of June 30, 2026, Delcath Systems had $95.9 million in cash and investments with no debt.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with revenue growth and increased guidance offset by a decrease in adjusted EBITDA and operating cash flow compared to the prior year.

Positives

• Total revenue increased by 20.1% to $29.1 million in Q2 2026 compared to $24.2 million in Q2 2025.
• HEPZATO KIT revenue grew by 20.4% to $27.1 million in Q2 2026 from $22.5 million in Q2 2025.
• Gross margins improved to 90% in Q2 2026 from 86% in Q2 2025.
• The company increased its 2026 full-year revenue guidance to $104 million $108 million.
• HEPZATO KIT volume is projected to grow by at least 28% in 2026 over 2025.
• The company maintains a strong cash position of $95.9 million with no debt as of June 30, 2026.
• Positive operating cash flow of $5.7 million was generated in Q2 2026.
• Independent investigators presented positive retrospective data showing a 60% hepatic partial response rate with percutaneous hepatic perfusion in heavily pretreated patients with liver-dominant metastatic breast cancer.

Negatives

• Non-GAAP adjusted EBITDA decreased to $7.6 million in Q2 2026 from $9.8 million in Q2 2025.
• Cash provided by operations decreased to $5.7 million in Q2 2026 from $7.3 million in Q2 2025.
• Research and development expenses increased to $10.4 million in Q2 2026 from $6.9 million in Q2 2025.
• Selling, general and administrative expenses increased to $13.4 million in Q2 2026 from $11.4 million in Q2 2025.

Risks

• Uncertainties related to the company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT.
• Potential challenges in managing the HEPZATO KIT supply chain and securing adequate components for manufacturing.
• Risks associated with successful FDA inspections of the company's and its third-party suppliers' facilities.
• Challenges in the successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy (REMS).
• Uncertainty regarding the potential benefits of the HEPZATO KIT for various liver-directed treatments.
• Risks related to obtaining reimbursement for the HEPZATO KIT.
• Potential difficulties in entering into necessary purchase and sale agreements with users of the HEPZATO KIT.
• The company acknowledges that new risk factors and uncertainties may emerge over time.

Future Outlook

The company has increased its 2026 full-year financial guidance, projecting total HEPZATO KIT and CHEMOSAT revenue to range from $104 million to $108 million, reflecting an anticipated increase in HEPZATO KIT volume of at least 28% over 2025. Full-year gross margins are expected to be in the range of 86% to 89%, with positive adjusted EBITDA anticipated.

Management Comments

• "Our strong second quarter, including total revenue of $29.1 million and quarterly operating cash flow of $5.7 million, reflects continued momentum in HEPZATO procedures," said Gerard Michel, Chief Executive Officer of Delcath Systems.
• "As we grow our active treatment center network and drive physician adoption, we are seeing increased usage of HEPZATO in combination with systemic therapies to treat metastatic uveal melanoma."
• "The growing clinical experience with this treatment strategy is strengthening physician confidence in HEPZATO and supporting its development as a multi-indication, liver-directed therapy platform, including colorectal and breast cancer."

Industry Context

StockSavvy.ai notes that Delcath Systems operates in the competitive interventional oncology market, focusing on liver-directed therapies. The company's performance, particularly the growth in HEPZATO KIT revenue and the increased full-year guidance, aligns with a trend of increasing adoption for specialized cancer treatments. However, the decrease in adjusted EBITDA and operating cash flow warrants attention, especially when compared to the company's revenue growth.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and raised guidance, but tempered by decreased EBITDA and operating cash flow.
• Employees: Continued investment in commercial expansion and R&D may lead to job growth.
• Customers (Patients): Access to and potential benefit from the HEPZATO KIT treatment for liver cancers.
• Healthcare Providers: Continued adoption and clinical experience with HEPZATO KIT and CHEMOSAT systems.
• Suppliers: Potential for increased demand for components related to HEPZATO KIT manufacturing.

Next Steps

• Continue to grow the active treatment center network.
• Drive physician adoption of HEPZATO.
• Further develop HEPZATO as a multi-indication, liver-directed therapy platform.
• Continue clinical trial activities, including the global Phase 2 trial of HEPZATO in combination with standard of care in patients with liver-dominant HER2-negative metastatic breast cancer.

Key Dates

Recommendation

The company demonstrates revenue growth and increased full-year guidance, which are positive indicators. However, the decrease in adjusted EBITDA and operating cash flow, coupled with increased operating expenses, suggests a need for caution. While the clinical data is promising, the path to sustained profitability requires further demonstration. Therefore, a 'hold' recommendation is appropriate pending clearer evidence of improved profitability and cash flow generation alongside continued revenue expansion.

Keywords

interventional oncology, liver cancer, HEPZATO KIT, CHEMOSAT, percutaneous hepatic perfusion, metastatic uveal melanoma, metastatic breast cancer, melphalan